Citadel Advisors’s Peak Bio, Inc. Common Stock PKBO Stock Holding History

Citadel Advisors’s Portfolio PKBO Stock Details PKBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-78,969	Closed	-$789K	–	15793
2022 Q3	$789K	Sell	78,969 -31,599	-29%	-$314K	﹤0.01%	7502
2022 Q2	$1.09M	Sell	110,568 -21	-0%	-$207	﹤0.01%	6822
2022 Q1	$1.09M	Hold	110,589	–	–	﹤0.01%	7506
2021 Q4	$1.08M	Sell	110,589 -670	-0.6%	-$6.55K	﹤0.01%	7764
2021 Q3	$1.09M	Sell	111,259 -3,725	-3%	-$36.1K	﹤0.01%	7925
2021 Q2	$1.11M	Buy	114,984 +178	+0.2%	+$1.73K	﹤0.01%	8087
2021 Q1	$1.11M	Buy	+114,806	New	+$1.11M	﹤0.01%	7849

Other funds holding PKBO

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors's PKBO Position: Q4 2022 in Review

Citadel Advisors sold out of Peak Bio, Inc. Common Stock (PKBO) in Q4 2022, closing a stake of 78,969 shares — an estimated $789K sold.

Citadel Advisors first reported a position in PKBO in Q1 2021 and held it in 7 quarters. The position peaked at $1.11M in Q2 2021. 9 funds tracked by Wall St. Rank hold PKBO as of Q4 2022.

Citadel Advisors reported no remaining Peak Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Citadel Advisors sold 78,969 Peak Bio, Inc. Common Stock shares in Q4 2022, an estimated $789K.
Citadel Advisors first reported a position in Peak Bio, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
Citadel Advisors's Peak Bio, Inc. Common Stock position peaked at $1.11M in Q2 2021.
9 funds tracked by Wall St. Rank held Peak Bio, Inc. Common Stock as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.